No Data
No Data
Barclays Maintains Prelude Therapeutics(PRLD.US) With Sell Rating, Cuts Target Price to $1
Cautious Outlook on Prelude Therapeutics: Sell Rating Amid Modest Trial Results and Market Skepticism
Buy Rating Affirmed for Prelude Therapeutics Amid Positive Developments in PRT3789 and Strong Financial Position
Prelude Therapeutics Presents New Data From Phase 1 Trial of PRT3789
Inception Fertility Announces the Acceptance of 36 Abstracts to Be Presented at the 2024 ASRM Scientific Congress
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium